{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:30:52Z","timestamp":1792859452007,"version":"4.5.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Alzheimer's disease is a neurological condition that causes the disruption of neuronal connections in the human brain. It is progressive and targets about 10% of the United States population over the age of 65.3 to date, there is no cure to the disease. Physicians can treat symptoms but lack the ability to stop the progression of the disease. However, promising research has come to the surface in recent years. A collection of these therapeutic targets, which have yielded positive results in mice models, are presented in this article. They include targets such as meningeal lymphatics, mitochondrial homeostasis, genomic instability, calcium homeostasis, and cold-shock proteins such as RNA-binding motif protein 3 and reticulon-3, high-density lipoprotein, and antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/bc.bc_20_21","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T01:08:37Z","timestamp":1647738517000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Mini review"],"prefix":"10.4103","volume":"8","author":[{"given":"Ruchi","family":"Mangal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240830","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MOL.0000000000000604","article-title":"HDL from an Alzheimer's disease perspective","volume":"30","author":"Button","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"R2-1-20240830","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2019.07.017","article-title":"Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites","volume":"16","author":"Angulo","year":"2020","journal-title":"Alzheimers Dement"},{"key":"R3-1-20240830","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41586-018-0368-8","article-title":"Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease","volume":"560","author":"Da Mesquita","year":"2018","journal-title":"Nature"},{"key":"R4-1-20240830","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00401-020-02234-7","article-title":"Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer's disease models and human brains","volume":"141","author":"Vaillant-Beuchot","year":"2021","journal-title":"Acta Neuropathol"},{"key":"R5-1-20240830","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-1-20240830","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1038\/s41467-020-16361-y","article-title":"HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer's disease","volume":"11","author":"Pao","year":"2020","journal-title":"Nat Commun"},{"key":"R7-1-20240830","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature14142","article-title":"RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration","volume":"518","author":"Peretti","year":"2015","journal-title":"Nature"},{"key":"R8-1-20240830","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.cub.2017.01.047","article-title":"RTN3 is a novel cold-induced protein and mediates neuroprotective effects of RBM3","volume":"27","author":"Bastide","year":"2017","journal-title":"Curr Biol"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_20_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:32Z","timestamp":1787166512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_20_21"}},"subtitle":["Prospective therapeutic targets of Alzheimer's disease"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_20_21","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}